Mesenchymal stem cells genetically modified by lentivirus-mediated interleukin-12 inhibit malignant ascites in mice

Experimental and Therapeutic Medicine

Volumn 8, Issue 4, 2014, Pages 1330-1334

  Han, Jiming ^a   Zhao, Jumei ^a   Xu, Jianrong ^b,c   Wen, Yanjun ^c  

^a YAN'AN UNIVERSITY   (China)

^b SOUTHWEST UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

Immunotherapy; Interleukin 12; Malignant ascites; Mesenchymal stem cells

Indexed keywords

INTERLEUKIN 12; LENTIVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES FLUID LEVEL; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE COUNT; FEMALE; HUMAN; HUMAN CELL; MALIGNANT ASCITES; MESENCHYMAL STEM CELL; MICROSCOPY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIDE EFFECT; SURVIVAL RATE;

EID: 84906487677     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.1918     Document Type: Article

References (16)

1. Scheithauer W, Kornek GV, Raderer M, et al: Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 21: 1307-1312, 2003.
2. Santini D, Massacesi C, D'Angelillo RM, et al: Raltitrexed plus weekly oxaliplatin as first-line chemotherapy in metastatic colorectal cancer: a multicenter non-randomized phase ii study. Med Oncol 21: 59-66, 2004.
3. Sartori S, Nielsen I, Tassinari D, Trevisani L, Abbasciano V and Malacarne P: Evaluation of a standardized protocol of intracavitary recombinant interferon alpha-2b in the palliative treatment of malignant peritoneal effusions. A prospective pilot study. Oncology 61: 192-196, 2001.
4. Walther W and Schlag PM: Current status of gene therapy for cancer. Curr Opin Oncol 25: 659-664, 2013.
5. Yoshiji H, Kuriyama S, Hicklin DJ, et al: The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model. Hepatology 33: 841-847, 2001.
6. Cheema TA, Fecci PE, Ning J and Rabkin SD: Immunovirotherapy for the treatment of glioblastoma. Oncoimmunology 3: e27218, 2014.
7. Marchi LH, Paschoalin T, Travassos LR and Rodrigues EG: Gene therapy with interleukin-10 receptor and interleukin-12 induces aprotective interferon-γ-dependent response against B16F10-Nex2 melanoma. Cancer Gene Ther 18: 110-122, 2011.
8. Quetglas JI, Dubrot J, Bezunartea J, et al: Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12. Mol Ther 20: 1664-1675, 2012
9. Dickerson EB, Akhtar N, Steinberg H, et al: Enhancement of the antiangiogenic activity of interleukin-12 by peptide targeted delivery of the cytokine to alphavbeta3 integrin. Mol Cancer Res 2: 663-673, 2004.
10. Wigginton JM, Gruys E, Geiselhart L, et al: IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest 108: 51-62, 2001.
11. Zhang L, Kerkar SP, Yu Z, et al: Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther 19: 751-759, 2011.
12. Kerkar SP, Muranski P, Kaiser A, et al: Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res 70: 6725-6734, 2010.
13. Parker JN, Meleth S, Hughes KB, Gillespie GY, Whitley RJ and Markert JM: Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. Cancer Gene Ther 12: 359-368, 2005.
14. Dai LJ, Moniri MR, Zeng ZR et al: Potential implications of mesenchymal stem cells in cancer therapy. Cancer Lett 305: 8-20, 2011.
15. Bexell D, Svensson A and Bengzon J: Stem cell-based therapy for malignant glioma. Cancer Treat Rev 39: 358-365, 2013.
16. Hu YL, Fu YH, Tabata Y and Gao JQ: Mesenchymal stem cells: a promising targeted-delivery vehicle in cancer gene therapy. J Control Release 147: 154-162, 2010.